Compare IOVA & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IOVA | RYTM |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7B | 6.3B |
| IPO Year | 2008 | 2017 |
| Metric | IOVA | RYTM |
|---|---|---|
| Price | $7.41 | $116.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 19 |
| Target Price | $14.50 | ★ $139.76 |
| AVG Volume (30 Days) | ★ 12.8M | 1.8M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 14.84 | ★ 28.34 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $58.86 | $74.20 |
| Revenue Next Year | $41.86 | $74.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.08 | $74.50 |
| 52 Week High | $15.37 | $122.20 |
| Indicator | IOVA | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 31.10 | 61.81 |
| Support Level | $3.57 | $82.31 |
| Resistance Level | $9.36 | N/A |
| Average True Range (ATR) | 0.57 | 8.19 |
| MACD | -0.13 | 1.40 |
| Stochastic Oscillator | 4.34 | 88.37 |
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.